Arvinas (ARVN) had its price target raised by Citigroup Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference [Yahoo! Finance]
Prostate Cancer Market Competitive Landscape Report 2026: Comprehensive Insights About 230+ Companies and 265+ Drugs by Product Type, Stage, and Route of Administration [Yahoo! Finance]
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials [Yahoo! Finance]